KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Chemed (CHE) Share-based Compensation (2016 - 2025)

Chemed (CHE) has 17 years of Share-based Compensation data on record, last reported at -$23.3 million in Q4 2025.

  • For Q4 2025, Share-based Compensation fell 175.61% year-over-year to -$23.3 million; the TTM value through Dec 2025 reached $1.1 million, down 96.49%, while the annual FY2025 figure was $1.1 million, 96.49% down from the prior year.
  • Share-based Compensation reached -$23.3 million in Q4 2025 per CHE's latest filing, down from $6.1 million in the prior quarter.
  • Across five years, Share-based Compensation topped out at $30.8 million in Q4 2024 and bottomed at -$23.3 million in Q4 2025.
  • Average Share-based Compensation over 5 years is $4.6 million, with a median of $7.9 million recorded in 2022.
  • Peak YoY movement for Share-based Compensation: skyrocketed 275.91% in 2021, then plummeted 402.38% in 2024.
  • A 5-year view of Share-based Compensation shows it stood at $21.3 million in 2021, then grew by 17.61% to $25.1 million in 2022, then tumbled by 183.45% to -$20.9 million in 2023, then skyrocketed by 246.91% to $30.8 million in 2024, then tumbled by 175.61% to -$23.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for Share-based Compensation were -$23.3 million in Q4 2025, $6.1 million in Q3 2025, and $9.2 million in Q2 2025.